Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic transplant patients with hematologic malignancies.

The latest Orca comes stacked with a sleek new cockpit, a set of high-tech OQUO hoops, and paint that hits harder than a mid-season ramp test ...

Louis Sauzedde is in the process of making a replica of 'Orca' the infamous fishing boat from the classic Steven Spielberg film, 'Jaws.' ...

Orca Bio is preparing to make a splash in the cell therapy market. The biotech has hired Steve Gavel as chief commercial officer, securing itself a leader with cell therapy expertise accrued at ...

ParTec will integrate ORCA’s capabilities into its AI Factory infrastructure, marking a step in expanding the practical use of quantum computing across enterprise and research applications.

Cloud cybersecurity firm Orca Security Ltd. today announced it acquired Opus Security Inc., a venture capital-funded startup that specializes in artificial intelligence-driven automation and ...

Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company’s manufacturing platform uses single-cell ...

Orca-T, an investigational allogeneic T-cell immunotherapy, improved cGVHD-free survival compared with allo-HSCT in patients with acute leukemia or MDS in the phase 3 Precision-T trial (NCT05316701).

Orca (ORCA) rallied to $5.06, growing by over 170% in hours after an Upbit listing. The rally caused significant short liquidations and market chaos, and ORCA was shorted again as the trend reversed.

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who received standard allogeneic stem cell transplant for hematologic malignancies.

Photos show all-white orca off Japanese coast It’s not clear whether the orca is a true albino or its white coloring was caused by another medical condition.